{"id":"W2136713872","doi":"10.2174/187153010790827993","title":"Imatinib Mesylate (Gleevec©): Targeted Therapy Against Cancer with Immune Properties","year":2010,"lang":"en","type":"review","venue":"Endocrine Metabolic & Immune Disorders - Drug Targets","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Institut National Du Cancer; Ligue Contre le Cancer; Institute of Cancer Research; Institut National de la Santé et de la Recherche Médicale","keywords":"Imatinib mesylate; Imatinib; Medicine; Targeted therapy; Tyrosine kinase; Tyrosine-kinase inhibitor; Cancer research; Immune system; Cancer; Pharmacology; Immunology; Internal medicine; Receptor; Myeloid leukemia","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0005141266,0.003009013,0.008368964,0.0008926783,0.0005374693,0.0001473238,0.001278324,0.000490673,0.001466221],"category_scores_gemma":[0.0002207626,0.001940227,0.002224032,0.001392143,0.0006443356,0.0004133834,0.0004446172,0.003238809,0.0004010014],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006409202,"about_ca_system_score_gemma":0.003507847,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002808493,"about_ca_topic_score_gemma":0.0002715344,"domain_scores_codex":[0.9909912,0.0005839277,0.002736917,0.001985654,0.00136807,0.002334216],"domain_scores_gemma":[0.9942965,0.0001674908,0.001783606,0.002869302,0.0003796341,0.000503487],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0004299358,0.001126689,0.00008595345,0.004999518,0.005687476,0.0001863439,0.0008794758,0.000009534672,0.000648713,0.00003495902,0.0004747233,0.9854367],"study_design_scores_gemma":[0.010734,0.0002171176,0.0002963351,0.007645094,0.003615712,0.0002167354,0.0001458605,0.00002870977,0.002775684,0.00001509667,0.9723713,0.001938312],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00344273,0.9838071,0.0000104193,0.0006033688,0.00163502,0.00753352,0.0002576404,0.0006575045,0.002052736],"genre_scores_gemma":[0.002405139,0.9766512,0.001034524,0.0002119225,0.0006111023,0.004751285,0.002274127,0.00090501,0.01115571],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9834984,"threshold_uncertainty_score":0.9994466,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02049554789560371,"score_gpt":0.2982617519964285,"score_spread":0.2777662041008248,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}